European Pharmaceutical Review

JUNE 18, 2024

The US Food and Drug Administration (FDA) has approved the first anti-PD-1 therapy in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. In the placebo plus carboplatin and paclitaxel arm, PFS was 6.5

Chemotherapy 105

Chemotherapy Research Laboratories FDA 105

Pharmaceutical Technology

SEPTEMBER 28, 2022

The approvals include Keytruda plus chemotherapy as neoadjuvant treatment and then continued as a single agent for adjuvant treatment post-surgery in hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. This approval is based on KEYNOTE-564 trial data.

Chemotherapy 59

Chemotherapy Research Laboratories Immunization 59

Pharmaceutical Technology

JUNE 28, 2022

The treatment is intended for breast cancer patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative who have previously received neoadjuvant or adjuvant chemotherapy. A PARP inhibitor, Lynparza is co-developed and co-marketed by Merck and AstraZeneca.

Research Laboratories 64

Research Laboratories Chemotherapy 64

pharmaphorum

OCTOBER 14, 2021

Keytruda (pembrolizumab) can be used in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent or metastatic cervical cancer where the tumour expresses a certain level of PD-L1. 0.77]; p<0.0001) compared to chemotherapy, with or without bevacizumab, where tumours expressed PD-L1 (CPS ?

Chemotherapy 45

Chemotherapy Research Laboratories Immunization FDA 45

European Pharmaceutical Review

AUGUST 12, 2024

It is the first anti-PD-1 therapy approved for use together chemotherapy in adults who have primary advanced or recurrent endometrial carcinoma, regardless of mismatch repair status. The bispecific antibody has shown potential to generate “significant and sustained reductions in B-cell populations”.

Research Laboratories 59

Research Laboratories Chemotherapy FDA 59

Pharmaceutical Technology

AUGUST 5, 2022

Earlier, these patients received neoadjuvant or adjuvant chemotherapy. Merck Research Laboratories global clinical development head, senior vice-president and chief medical officer Dr Eliav Barr said: “The approval offers patients with germline BRCA-mutated, HER2-negative early-stage breast cancer a new, much-needed treatment option.

Research Laboratories 59

Research Laboratories Chemotherapy FDA 59

Pharmaceutical Technology

APRIL 4, 2023

The combination therapy can be used to treat la/mUC patients who do not qualify for cisplatin-containing chemotherapy. KEYTRUDA is an anti-PD-1 therapy developed by Merck, while Padcev has been developed by Astellas and Seagen. Results showed that patients treated with Padcev along with KEYTRUDA achieved a confirmed ORR of 68%.

Research Laboratories 52

Research Laboratories Chemotherapy FDA 52